What is Reliefband Technologies?
Reliefband Technologies operates at the intersection of consumer health and clinical-grade medical technology. The company specializes in the development of non-drowsy, drug-free wearable devices engineered to mitigate nausea and vomiting associated with motion sickness, pregnancy, chemotherapy, and migraines. By leveraging patented nerve stimulation technology, the firm provides a non-pharmacological alternative to traditional anti-emetic medications, effectively eliminating the common side effects associated with chemical interventions.
The company's market position is bolstered by its FDA-cleared status, which facilitates adoption within both direct-to-consumer channels and professional clinical environments. By focusing on rapid-response therapeutic outcomes, Reliefband has established a robust brand identity as a leader in the wearable neuromodulation space, catering to a diverse demographic that prioritizes safety and efficacy in symptom management.
How much funding has Reliefband Technologies raised?
Reliefband Technologies has raised a total of $7.8M across 3 funding rounds:
Private Equity
$1.8M
Private Equity
$5M
Debt
$1M
Private Equity (2015): $1.8M, investors not publicly disclosed
Private Equity (2015): $5M, investors not publicly disclosed
Debt (2017): $999K, investors not publicly disclosed
Key Investors in Reliefband Technologies
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Reliefband Technologies?
With the recent influx of capital, Reliefband Technologies is well-positioned to accelerate its research and development pipeline and expand its commercial footprint. The strategic focus will likely shift toward enhancing the accessibility of its neuromodulation devices, potentially through expanded distribution partnerships and deeper integration into oncology and prenatal care protocols. As the health-tech landscape continues to favor non-invasive, data-driven therapeutic solutions, the company is poised to leverage its existing intellectual property to capture a larger share of the global nausea management market.
Future growth initiatives will likely prioritize the scaling of manufacturing capabilities to meet rising demand while maintaining the rigorous quality standards required for medical-grade hardware. By continuing to bridge the gap between clinical efficacy and consumer convenience, Reliefband Technologies remains a pivotal player in the evolution of digital health and personalized therapeutic interventions.
